Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
31.10.2023 - FOSTER CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) - Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today ... Seite 1
Source: wallstreet-online.de